2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002

Vasogen to Conduct Quarterly Conference Call

Toronto, Ontario - October 05, 2005

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease, will release its quarterly results after the close of the North American financial markets on Wednesday, October 12, 2005. A conference call will follow at 4:30 p.m. Eastern Time, during which management will provide a company update and discuss third quarter results. Participants are invited to attend by connecting 10 minutes prior to the call to one of the following:

Audio Web Cast*	www.vasogen.com
Direct Dial	416-695-5259
Toll-free	1-877-461-2816

A re-broadcast of the conference call may be accessed by:

Audio Web Cast*	www.vasogen.com
Direct Dial	1-888-330-1960 Pin code: 6691

Windows Media Player required*

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company’s lead product, the Celacade™ technology, is currently in two pivotal phase III clinical trials designed to support regulatory approval in North America and commercialization in North America and Europe. The 550-patient pivotal phase III SIMPADICO trial, which is designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease, is being closed out at 50 centers in North America and is expected to report initial results in late 2005. The 2,400-patient pivotal phase III ACCLAIM trial, designed to further investigate the use of Celacade technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure, is fully enrolled and ongoing at 176 clinical centers in North America, Europe, and Israel. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs.